|1.||Gaidarov, Ibragim: 1 article (10/2013)|
|2.||Unett, David J: 1 article (10/2013)|
|3.||Chen, Xiaohua: 1 article (10/2013)|
|4.||Liaw, Chen: 1 article (10/2013)|
|5.||Maciejewski-Lenoir, Dominique: 1 article (10/2013)|
|6.||Anthony, Todd: 1 article (10/2013)|
|7.||Martres, Paul: 1 article (01/2009)|
|8.||Wagner, John A: 1 article (10/2008)|
|9.||Lai, Eseng: 1 article (10/2008)|
|10.||Connolly, Daniel T: 1 article (10/2008)|
10/01/2008 - "Treatment with MK-0354 for 7 days resulted in plasma FFA suppression with minimal cutaneous flushing. "
10/01/2013 - "MK-0354 does not induce niacin-like GPR109A signaling in macrophages, suggesting that biased agonists devoid of the flushing side-effect may also lack properties required for macrophage-mediated anti-atherosclerotic effects. "
10/01/2013 - "In Langerhans cells, niacin initiates GPR109A-mediated signaling pathways (Erk1/2 and Ca(2+)) responsible for the release of vasodilatory prostanoids, while the synthetic GPR109A agonist MK-0354 fails to elicit any signaling, providing a mechanistic basis for the latter compound's inability to cause flushing. "
01/01/2009 - "One of them, MK-0354, has been tested in phase II studies, but despite significant decreases in Free Fatty Acid levels with absence of flushing events in clinical studies, it failed to demonstrate effects on LDL-Cholesterol, Triglycerides and HDL-Cholesterol. "
10/01/2008 - "In the Phase II study, MK-0354 2.5 g produced little flushing but no clinically meaningful effects on lipids (placebo-adjusted percent change: high-density lipoprotein cholesterol, 0.4%, 95% confidence interval -5.2 to 6.0; low-density lipoprotein cholesterol, -9.8%, 95% confidence interval -16.8 to -2.7; triglyceride, -5.8%, 95% confidence interval -22.6 to 11.9). "
|5.||Niacin (Nicotinic Acid)
|7.||Nonesterified Fatty Acids (NEFA)